小动物中的螺旋藻补充剂性能和产品属性:一个元分析
Frediansyah Firdaus1, Tanda Sahat Panjaitan1, Malik Makmur1,2
1Research Centre for Animal Husbandry, National Research and Innovation Agency, Bogor, Indonesia.
Animal bioscience
|April 11, 2025
概括
螺旋藻补充剂显著改善了山羊和绵羊的生长,肉质和抗氧化剂状况. 这种富含营养的藻类提高了动物的生产力,并为健康提供了好处,使其成为一种有价值的料添加剂.
科学领域:
- 动物科学动物科学
- 营养科学 营养科学
- 农业科学 农业科学
背景情况:
- 螺旋藻是一种营养丰富的蓝藻,具有潜在的健康益处.
- 小杂动物 (山羊和绵羊) 是全球重要的牲畜.
- 优化他们的营养是提高生产力和产品质量的关键.
研究的目的:
- 通过元分析,评估小反动物中螺旋藻补充剂的营养益处.
- 评估其对生长,乳头功能,抗氧化剂状况,血液生物化学,脂肪酸概况和肉质的影响.
主要方法:
- 2012年至2023年间发表的研究的系统审查和元分析.
- 包括来自Scopus,PubMed和Google Scholar等数据库的24项原始研究研究.
- 使用OpenMEE软件进行统计分析,通过PET-PEESE和Rosenthal的故障安全N.评估出版偏差.
主要成果:
- 螺旋藻补充剂显著提高了生长性能 (平均每日增长) 并降低了料转换率.
- 观察到抗氧化酶活性升高 (catalase,谷氨过氧化酶,超氧化物失调酶).
- 改善了肉类质量参数 (脂肪点,肌内脂肪,pH) 和有利的脂肪酸概况.
结论:
- 螺旋藻补充剂对小反动物的生产力,健康和肉质有显著的益处.
- 它代表了山羊和绵羊的宝贵食补充剂.
- 建议进行进一步的研究,以优化补充策略并阐明潜在机制.
相关概念视频
Tonicity in Animals
111.5K
The tonicity of a solution determines if a cell gains or loses water in that solution. The tonicity depends on the permeability of the cell membrane for different solutes and the concentration of nonpenetrating solutes in the solution within and outside of the cell. If a semipermeable membrane hinders the passage of some solutes but allows water to follow its concentration gradient, water moves from the side with low osmolarity (i.e., less solute) to the side with higher osmolarity (i.e.,...
111.5K
Drug Product Performance: In Vitro–In Vivo Correlation
431
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226


